Renal protective effect of RAAS blockade across the renal continuum, with a review of the efficacy and safety of valsartan

References

• National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49(2 Suppl. 2):S12-S154
   PubMed Web of Science ®Google Scholar
• Alebiosu CO, Ayodele OE The global burden of chronic kidney disease and the way forward. Ethn Dis 2005;15:418-23
   PubMed Web of Science ®Google Scholar
• Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation 2006;114:2871-91
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137-47
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72
   PubMed Web of Science ®Google Scholar
• Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-69
   PubMed Web of Science ®Google Scholar
• Schiffrin EL, Lipman ML, Mann JF Chronic kidney disease: effects on the cardiovascular system. Circulation 2007;116:85-97
   PubMed Web of Science ®Google Scholar
• Sego S. Pathophysiology of diabetic nephropathy. Nephrol Nurs J 2007;34:631-3
   PubMedGoogle Scholar
• Nickenig G, Ostergren J, Struijker-Boudier H. Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers. J Renin Angiotensin Aldosterone Syst 2006;7(Suppl. 1):S1-S7
   PubMed Web of Science ®Google Scholar
• Atlas SA The renin–angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007;13(8 Suppl. S-b):S9-S20
   PubMed Web of Science ®Google Scholar
• Jandeleit-Dahm KA, Tikellis C, Reid CM, et al. Why blockade of the renin–angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005;23:463-73
   PubMed Web of Science ®Google Scholar
• Leiter LA, Lewanczuk RZ Of the renin-angiotensin system and reactive oxygen species: Type 2 diabetes and angiotensin II inhibition. Am J Hypertens 2005;18:121-8
   PubMed Web of Science ®Google Scholar
• McGuire DK, Winterfield JR, Rytlewski JA, et al. Blocking the renin–angiotensin–aldosterone system to prevent diabetes mellitus. Diab Vasc Dis Res 2008;5:59-66
   PubMed Web of Science ®Google Scholar
• Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin–angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366:2026-33
   PubMed Web of Science ®Google Scholar
• Balamuthusamy S, Srinivasan L, Verma M, et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J 2008;155:791-805
   PubMed Web of Science ®Google Scholar
• Shoda J, Kanno Y, Suzuki H. A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy. Intern Med 2006;45:193-8
   PubMed Web of Science ®Google Scholar
• Barnett A. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial. J Am Soc Nephrol 2006;17:S132-S135
   PubMed Web of Science ®Google Scholar
• Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51
   PubMed Web of Science ®Google Scholar
• Strippoli GF, Bonifati C, Craig M, et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006 Issue 4. Art. No.: CD006257. DOI: 10.1002/14651858.CD006257
   Web of Science ®Google Scholar
• Takahashi A, Takase H, Toriyama T, et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis – a randomized study. Nephrol Dial Transplant 2006;21:2507-12
   PubMed Web of Science ®Google Scholar
• Efrati S, Zaidenstein R, Dishy V, et al. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002;40:1023-9
   PubMed Web of Science ®Google Scholar
• Israili ZH Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000;14(Suppl. 1):S73-S86
   PubMedGoogle Scholar
• Dandona P, Kumar V, Aljada A, et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab 2003;88:4496-501
   PubMed Web of Science ®Google Scholar
• Willemsen JM, Westerink JW, Dallinga-Thie GM, et al. Angiotensin II type 1 receptor blockade improves hyperglycemia-induced endothelial dysfunction and reduces proinflammatory cytokine release from leukocytes. J Cardiovasc Pharmacol 2007;49:6-12
   PubMed Web of Science ®Google Scholar
• Hirooka Y, Kimura Y, Sagara Y, et al. Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension. Clin Exp Hypertens 2008;30:267-76
   PubMed Web of Science ®Google Scholar
• Klingbeil AU, John S, Schneider MP, et al. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003;16:123-8
   PubMed Web of Science ®Google Scholar
• Li QZ, Deng Q, Li JQ, et al. Valsartan reduces interleukin-1β secretion by peripheral blood mononuclear cells in patients with essential hypertension. Clin Chim Acta 2005;355:131-6
   PubMed Web of Science ®Google Scholar
• Liu L, Zhao SP, Zhou HN, et al. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension. J Cardiovasc Pharmacol 2007;50:50-5
   PubMed Web of Science ®Google Scholar
• Manabe S, Okura T, Watanabe S, et al. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 2005;46:735-9
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Rifai N, et al. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension 2006;48:73-9
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Malacco E, Khder Y, et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther 2005;27:578-87
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Zannad F, Radauceanu A, et al. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. Am J Cardiol 2007;100:222-6
   PubMed Web of Science ®Google Scholar
• Ogawa S, Mori T, Nako K, et al. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension 2006;47:699-705
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Kariisa M, Dellegrottaglie S, et al. Angiotensin receptor blockade improves vascular compliance in healthy normotensive elderly individuals: results from a randomized double-blind placebo-controlled trial. J Clin Hypertens (Greenwich) 2006;8:783-90
   PubMedGoogle Scholar
• Kosch M, Levers A, Lang D, et al. A randomized, double-blind study of valsartan versus metoprolol on arterial distensibility and endothelial function in essential hypertension. Nephrol Dial Transplant 2008;23:2280-5
   PubMed Web of Science ®Google Scholar
• Ichihara A, Kaneshiro Y, Takemitsu T, et al. Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients. J Hum Hypertens 2006;20:787-94
   PubMed Web of Science ®Google Scholar
• Savoia C, Touyz RM, Endemann DH, et al. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients. Hypertension 2006;48:271-7
   PubMed Web of Science ®Google Scholar
• Nomura S, Shouzu A, Omoto S, et al. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res 2006;117:385-92
   PubMed Web of Science ®Google Scholar
• Higuchi T, Abletshauser C, Nekolla SG, et al. Effect of the angiotensin receptor blocker Valsartan on coronary microvascular flow reserve in moderately hypertensive patients with stable coronary artery disease. Microcirculation 2007;14:805-12
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Saglam M, Sonmez A, et al. Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan. Blood Purif 2007;25:327-35
   PubMed Web of Science ®Google Scholar
• Estacio RO, Coll JR, Tran ZV, et al. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Am J Hypertens 2006;19:1241-8
   PubMed Web of Science ®Google Scholar
• Hollenberg NK, Parving HH, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007;25:1921-6
   PubMed Web of Science ®Google Scholar
• Karalliedde J, Smith A, DeAngelis L, et al. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension 2008;51:1617-23
   PubMed Web of Science ®Google Scholar
• Katayama K, Nomura S, Ishikawa H, et al. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria. Kidney Int 2006;70:151-6
   PubMed Web of Science ®Google Scholar
• Katayama S, Yagi S, Yamamoto H, et al. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study. Hypertens Res 2007;30:529-33
   PubMed Web of Science ®Google Scholar
• Menne J, Farsang C, Deák L, et al. Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. J Hypertens 2008;26:1860-7
   PubMed Web of Science ®Google Scholar
• Muirhead N, Feagan BF, Mahon J, et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial. Curr Ther Res 1999;60:650-60
   Web of Science ®Google Scholar
• Uzu T, Sawaguchi M, Maegawa H, et al. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 2007;30:1581-3
   PubMed Web of Science ®Google Scholar
• Suzuki K, Souda S, Ikarashi T, et al. Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy. Diabetes Res Clin Pract 2002;57:179-83
   PubMed Web of Science ®Google Scholar
• Viberti G, Wheeldon NM Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-8
   PubMed Web of Science ®Google Scholar
• Jacobsen P, Andersen S, Jensen BR, et al. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003;14:992-9
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Aldigier JC, Ponticelli C, et al. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 2000;18:89-95
   PubMed Web of Science ®Google Scholar
• Hermida RC, Calvo C, Ayala DE, et al. Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension 2005;46:960-8
   PubMed Web of Science ®Google Scholar
• Watanabe S, Okura T, Kurata M, et al. Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension. Clin Exp Hypertens 2006;28:451-61
   PubMed Web of Science ®Google Scholar
• Palmer BF Supratherapeutic doses of angiotensin receptor blockers to decrease proteinuria in patients with chronic kidney disease. Am J Nephrol 2008;28:381-90
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8
   PubMed Web of Science ®Google Scholar
• Bakris GL, Ruilope L, Locatelli F, et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 2007;72:879-85
   PubMed Web of Science ®Google Scholar
• Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-53
   PubMed Web of Science ®Google Scholar
• Messerli FH The sudden demise of dual renin–angiotensin system blockade or the soft science of the surrogate end point. J Am Coll Cardiol 2009;53:468-70
   PubMed Web of Science ®Google Scholar
• Berns JS Is angiotensin-converting enzyme inhibitor and angiotensin receptor blocker combination therapy better than monotherapy and safe in patients with CKD?. Am J Kidney Dis 2009;53:192-6
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Bakris GL Renin-angiotensin blockade and kidney disease. Lancet 2008;372:511-12
   PubMed Web of Science ®Google Scholar
• Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-46
   PubMed Web of Science ®Google Scholar
• Sato A, Saruta T, Funder JW Combination therapy with aldosterone blockade and renin–angiotensin inhibitors confers organ protection. Hypertens Res 2006;29:211-16
   PubMed Web of Science ®Google Scholar
• Bomback AS, Klemmer PJ The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007;3:486-92
   PubMedGoogle Scholar
• Rossi GP Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists?. Curr Hypertens Rep 2006;8:262-8
   PubMed Web of Science ®Google Scholar
• Yoneda T, Takeda Y, Usukura M, et al. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. Am J Hypertens 2007;20:1329-33
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-51
   PubMed Web of Science ®Google Scholar
• Hauben M, Reich L, Gerrits CM, et al. Detection of spironolactone-associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES). Drug Saf 2007;30:1143-9
   PubMed Web of Science ®Google Scholar
• Galle J, Schwedhelm E, Pinnetti S, et al. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008;23:3174-83
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
   PubMed Web of Science ®Google Scholar
• Ishimitsu T, Kameda T, Akashiba A, et al. Effects of valsartan on the progression of chronic renal insufficiency in patients with nondiabetic renal diseases. Hypertens Res 2005;28:865-70
   PubMed Web of Science ®Google Scholar
• Perico N, Spormann D, Peruzzi E, et al. Efficacy and tolerability of valsartan compared with lisinopril in patients with hypertension and renal insufficiency. Clin Drug Invest 1997;14:252-9
   Web of Science ®Google Scholar
• Campbell R, Sangalli F, Perticucci E, et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003;63:1094-103
   PubMed Web of Science ®Google Scholar
• Segura J, Praga M, Campo C, et al. Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses. J Renin Angiotensin Aldosterone Syst 2003;4:43-7
   PubMed Web of Science ®Google Scholar
• Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-24
   PubMed Web of Science ®Google Scholar
• Kunz R, Wolbers M, Glass T, et al. The COOPERATE trial: a letter of concern. Lancet 2008;371:1575-6
   PubMed Web of Science ®Google Scholar
• Kunz R, Friedrich C, Wolbers M, et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008;148:30-48
   PubMed Web of Science ®Google Scholar
• Burgess E, Muirhead N, Rene de Cotret P, et al. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009;20:893-900
   PubMed Web of Science ®Google Scholar
• Muirhead N, House A, Hollomby DJ, et al. Effect of valsartan on urinary protein excretion and renal function in patients with chronic renal allograft nephropathy. Transplant Proc 2003;35:2412-14
   PubMed Web of Science ®Google Scholar
• Suzuki H, Kanno Y, Sugahara S, et al. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004;43:1056-64
   PubMed Web of Science ®Google Scholar
• Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999;21:23-33
   PubMed Web of Science ®Google Scholar
• Bakris GL, Kuritzky L. Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians. Postgrad Med 2009;121:51-60
   PubMed Web of Science ®Google Scholar
• Bakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int 2000;58:2084-92
   PubMed Web of Science ®Google Scholar
• Durmus A, Dogan E, Erkoc R, et al. Effect of valsartan on erythropoietin and hemoglobin levels in stage III-IV chronic kidney disease patients. Int J Clin Pract 2005;59:1001-4
   PubMed Web of Science ®Google Scholar
• Robles NR, Angulo E, Grois J, et al. Comparative effects of fosinopril and irbesartan on hematopoiesis in essential hypertensives. Ren Fail 2004;26:399-404
   PubMed Web of Science ®Google Scholar
• Marathias KP, Agroyannis B, Mavromoustakos T, et al. Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Curr Top Med Chem 2004;4:483-6
   PubMed Web of Science ®Google Scholar
• Haller H, Viberti GC, Mimran A, et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens 2006;24:403-8
   PubMed Web of Science ®Google Scholar
• U.S. National Institutes of Health. Aliskiren trial in type 2 diabetes using cardiovascular and renal disease endpoints (ALTITUDE). ClinicalTrials.gov, 2008. Available at: http://www.clinicaltrials.gov/ct/show/NCT00549757 [Last accessed 23 April 2009]
   Google Scholar
• U.S. National Institutes of Health. Olmesartan medoxomil in diabetes mellitus. ClinicalTrials.gov, 2008. Available at: http://www.clinicaltrials.gov/ct/show/NCT00185159 [Last accessed 2 October 2008]
   Google Scholar
• Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991;121:1244-63
   PubMed Web of Science ®Google Scholar